FRA:GU5's Return-on-Tangible-Equity is ranked worse than 53.15% of 111
companies
in the Medical Distribution industry
Industry Median: 8.81
vs FRA:GU5: 8.64
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Return-on-Tangible-Equity Related Terms
Guangzhou Baiyunshan Pharmaceutical Holdings Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Return-on-Tangible-Equity Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
FRA:GU5 vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Return-on-Tangible-Equity vs Medical Distribution Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.96% mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Return-on-Tangible-Equity of 20.96% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. This is 55% above median its historical median of 13.51. Over the past decade, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Return-on-Tangible-Equity has ranged from 8.64 to 18.12. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #59 out of 111 companies in the Medical Distribution industry, placing it in the top 53.2%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Return-on-Tangible-Equity too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Return-on-Tangible-Equity of 20.96% is 55% above median its 10-year median of 13.51. Over the past 10 years, this metric has ranged from a low of 8.64 to a high of 18.12. The Medical Distribution industry median Return-on-Tangible-Equity is 8.81. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 20.96% is 137.9% above this industry median. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #59 out of 111 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #59 out of 111 companies for Return-on-Tangible-Equity. This places Guangzhou Baiyunshan Pharmaceutical Holdings Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.81. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 20.96% is 137.9% above this benchmark. Historically, Guangzhou Baiyunshan Pharmaceutical Holdings Co's own Return-on-Tangible-Equity has ranged from 8.64 to 18.12 over the past decade. While the company's 10-year median is 13.51 vs. the industry median of 8.81, Guangzhou Baiyunshan Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.81, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Return-on-Tangible-Equity of 20.96% is 137.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Return-on-Tangible-Equity is 20.96%, which is 55% above median its own 10-year median of 13.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.39, compared to a current price of €1.66 — trading 30.5% below its estimated fair value. The current Return-on-Tangible-Equity is 20.96%, which is 55% above median its 10-year median of 13.51 and 137.9% above the Medical Distribution industry median of 8.81. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Return-on-Tangible-Equity is 20.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.66 is trading 30.5% below its estimated GF Value™ of €2.39.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.
Key valuation signals for FRA:GU5:
Return-on-Tangible-Equity: 20.96% (55% above median its 10-year median of 13.51)
GF Value™: €2.39 vs. price of €1.66 (30.5% below fair value)
Industry Position: 137.9% above the Medical Distribution median (#59 of 111)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
71GF Score
Get the complete analysis for FRA:GU5
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
